Tag: ibogaine

  • The Role of Psychedelic Plant Medicines in Addiction Treatment

    Psychedelic plant medicines have been used for healing purposes by indigenous cultures for thousands of years, and there is mounting evidence that shows their ability to integrate with modern addiction therapy. 

    Psychedelic plant medicines have the potential to help many people who are in recovery from substance use disorder dig deep into the roots of their addiction and come out of the other side. Plant medicines like psilocybin, ayahuasca, and particularly ibogaine, have demonstrated unprecedented results for those who use them as a tool on their recovery journey.

    While the legal status of many of these substances is still murky (depending on where you consume them), the ongoing research, decriminalization efforts, and shift in public narrative is promising. Hope lies on the horizon for wider access to these medicines, but right now, what’s needed is raising awareness and informed decision-making around their consumption.

    Here is how psychedelic plant medicines can help those that struggle with addiction and what people should consider before choosing this path.

    Ancient healing practices reconcile with modern science

    Psychedelic plant medicines have been used for healing purposes by indigenous cultures for thousands of years, and there is mounting evidence that shows their ability to integrate with modern addiction therapy. 

    Research around the potential of ibogaine to treat opiate addiction is still in its infancy, but shows promising results. Ibogaine, which comes from the Iboga shrub, has been used historically in ceremonies in West Africa by practitioners of the Bwiti spiritual tradition since the late nineteenth century. The roots and bark of the tree are consumed ceremoniously in large doses to provoke a near-death experience, and in smaller doses during rituals and tribal dances. It is not considered a recreational substance by users, yet is classified as a Schedule 1 drug in the US.

    One 2017 study funded by the Multidisciplinary Association for Psychedelic Studies (MAPS) observed opiate addiction treatment delivered by two independent ibogaine clinics in Mexico. One month after the study, half of participants reported using no opiates in the month following the study. The researchers found that “ibogaine was associated with substantive effects on opioid withdrawal symptoms and drug use in subjects for whom other treatments had been unsuccessful.” 

    Another study on the long-term efficacy of ibogaine-assisted therapy in New Zealand found that a single ibogaine treatment reduced opioid symptoms and resulted in no opioid use or reduced use in dependent individuals over 12 months. 

    Healing that gets to the root

    Ayahuasca is a psychoactive Amazonian brew traditionally used in the indigenous communities of South America. Research on the brew is grounded in its potential to support healing by allowing for a deeper connection to oneself and due to the spiritual context in which it is taken. 

    One 2017 study published in the International Journal on Drug Policy used qualitative analysis through long-term field work and participant observation in ayahuasca communities, as well as conducting interviews with participants with problems of substance abuse.

    The study found that “ayahuasca’s efficacy in the treatment of addiction blends somatic, symbolic, and collective dimensions. The layering of these effects, and the direction given to them through ritual, circumscribes the experience and provides tools to render it meaningful.”

    Researchers from a 2013 Canadian study, sponsored by MAPS, concluded that ayahuasca-assisted therapy for stress and addiction was correlated with improved mindfulness, empowerment, hopefulness, and quality of life-outlook and quality of life-meaning. The same study found that ayahuasca, when administered in a ceremonial setting, may have contributed to reduction in cocaine use in dependent participants.

    There have also been studies that show the benefit of psilocybin mushrooms in allowing people to overcome addictive or damaging behavior. A 2014 study from the Johns Hopkins Center for Psychedelic and Consciousness Research found that 80% of previously addicted smokers abstained from smoking six months after they were administered psilocybin. Remarkably, 60% continued to abstain two and a half years after the study.

    “Institutions like MAPS and the Imperial College London are pioneering the way forward with this evidence-based approach to psychedelic medicine—a necessary effort if these compounds are to be integrated into the mainstream,” said Gaurav Dubey, clinical biologist and content editor at Microdose Psychedelic Insights.

    “Though, we have a lot of catching up to do,” said Dubey. “We need to do better in understanding the psychotherapeutic mechanisms of these incredibly unique compounds and the only way to uncover that is through science and research.

    “The clinical data that strongly supports the therapeutic use of these compounds in addiction treatment will be fundamental in making them accessible to recovering addicts around the globe,” he added.

    Journeys to an addiction-free life, supported by plant medicines

    Kat Courtney is the founder of AfterLife Coaching, a trained ayahuasquera, and has been working with the plant medicine ayahuasca for over a decade. Courtney first began her journey with ayahuasca in Peru in 2006, while suffering with alcoholism and bulimia.

    “Not only did ayahuasca help me face and deal with the traumas and programming that created these destructive behaviors, she helped me access an authentic space of self love and gave me tools to work with in lieu of the addictions,” said Courtney.

    “They fast-track the healing and awakening process and ground us into our bodies so we can move past stages of self-destruction. They help us to move the trauma that is stored in the body through crying, purging, and all kinds of different forms of release.”

    But Courtney stresses that the act of taking these medicines is only part of the deal: “We absolutely have to be committed to integrating these experiences and making the life changes that support sobriety,” explained Courtney. “Otherwise, plant medicine ceremonies can become distant memories.”

    Alternative approaches offer a chance for healing

    Aeden Smith-Ahearn is the founder of Experience Ibogaine Clinic, based in Mexico. Aeden first tried ibogaine in an effort to overcome his dependency on multiple substances, including heroin

    “Ibogaine got me comfortably off opiates,” said Smith-Ahearn. “I had almost no withdrawal symptoms, and I had a very profound experience which helped give me a motivational boost in the right direction.

    “The medicine put me in my place, and that’s exactly where I needed to be. I got a fresh start, on top of a head start into my recovery,” he explained.

    Prior to his ibogaine experience, Smith-Ahearn had tried several programs in an attempt to break free from his addictions, which he describes as “cold turkey, three meals a day, and a therapist once a week.”

    “These programs work for many people, but they didn’t do the job for me. The problem was that I did not want to change, and was therefore unwilling to work towards something I didn’t want,” he said.

    Smith-Ahearn credits ibogaine with huge potential for recovering opiate addicts specifically because of how it interacts with the brain’s receptors. “The hardest part about breaking out of opiate addiction is getting over withdrawals,” he said. “The medicine alleviates withdrawal symptoms [for some patients], which is a godsend for someone who is in over their head with opiate addiction.”

    Like Courtney, Smith-Ahearn stresses that ibogaine is not a cure-all. “It’s crucial that patients of the treatment put their effort into a quality aftercare plan.”

    Charles Johnston, director of client success at Clear Sky Recovery, has also historically struggled with opiate addiction and subsequently used ibogaine as a tool to help him overcome his dependency.

    “Ibogaine was the medicine that interrupted my addiction, and for the first time let me fully witness the root cause of my addiction: self-hatred. It provided me with a path, purpose, and mission to support others and see that addiction is a blessing of self-discovery,” explained Johnston.

    “Ibogaine allows the individual to feel how they would after months of detox with conventional methods and if supported properly, encourages a whole new paradigm of accountability and acceptance,” he continued.

    With these and other accounts of personal transformation, it’s clear that ayahuasca and ibogaine have potential to assist people struggling with addiction on a path to recovery. However, these treatments should not be treated lightly and come with a number of risks to the patient if not administered responsibly.

    What you need to consider before trying psychedelic therapy

    Psychedelics generally have very little risk of abuse, but when taken in the wrong setting, or without proper guidance or structured preparation and integration, they can result in negative consequences.

    There are some short term health risks which are important to consider. “Using ibogaine comes with risks to your physical health, such as seizures, gastrointestinal issues, heart complications, and ataxia,” says board-certified psychiatrist and addiction specialist Dr. Zlatin Ivanov. “There have also been unexplained fatalities in people who have ingested ibogaine, which may be linked to the treatment.”

    Charles Johnston of Clear Sky Recovery explained that “if someone has heart issues, liver problems, other major health complications, serious psychological issues, or are expecting a quick fix, ibogaine may not be the right path.”

    The same largely goes for users of other plant medicines, including ayahuasca. Users of SSRI antidepressant medication have run into an adverse reaction while drinking the medicine with the drugs still in their system.

    “People need to do careful research and not fall foul of misleading things that they see on the internet. A lot of people have expectations that the medicine may not offer, like profound psychedelic experiences guaranteed to change them or no withdrawal whatsoever,” said Aeden Smith-Ahearn of Experience Ibogaine.

    Those seeking treatment with psychedelic plant medicines should make sure they go to a reliable and reputable center. In recent years, the number of tourists flocking to Peru to drink ayahuasca has boomed, resulting in illegitimate retreats run by people lacking in the experience required to administer the medicine.

    In many countries, including the US, these substances are illegal to consume. Many people do however seek out treatment in countries where the medicines are not outlawed, such as Mexico, Costa Rica, Peru, and Colombia. In the US, ayahuasca is legal within specific religious groups, such as the Santo Daime.

    A path to accessibility

    Looking ahead to the future of psychedelic treatment, progress is being made on the legalization front, with Oakland and Santa Cruz, California, and Denver, Colorado, voting for decriminalization of psilocybin-containing mushrooms in 2019 and 2020. Oregon and Washington D.C. also have votes ahead on the decriminalization of psychedelic-containing plants and fungi.

    Meanwhile, Canada is seeing a number of legal ayahuasca centers open up, on the part of religious groups who have special permission from the government to use the medicine. However, ultimately, it will be a continuation of the scientific research that paves the way for increased access to psychedelic therapy.

    “We need more large scale, gold-standard clinical trials examining these compounds in the context of addiction treatment, such that their impact can no longer be ignored—even by the most stubborn of policymakers and world leaders,” said Dubey.

    “There needs to be a shift in global drug policy so these powerful medicines can be reclassified and reintegrated into our society in an effort to heal the masses.”

    In essence, psychedelics need to go mainstream and lose the stigma that they have held for decades so that the public appetite can develop and further drive policy changes. In addition to research, diverse voices and experiences, along with mainstream support, will be key in the psychedelic renaissance maintaining its momentum.

    The value of psychedelic plant medicines for addiction recovery is difficult to overstate, but is a path that should be explored carefully, mindfully, and while armed with the right information and support. And there’s hope that a future where accessibility isn’t an issue is on the horizon: The ongoing research and changing societal attitudes towards psychedelic plant medicines demonstrate promise. Education around these medicines and their proper use is vital for this renaissance to continue.

    By shining a light on the potential of psychedelic plant medicines to help and heal, we can contribute to forming more pathways to change and legitimate channels for people to benefit from their treatment.

    View the original article at thefix.com

  • Ibogaine: Promising Addiction Treatment or Snake Oil?

    Ibogaine: Promising Addiction Treatment or Snake Oil?

    The induced vivid hallucinations and memories of childhood and formative experiences seem to be the key to ibogaine’s effectiveness in treating addiction, but experts don’t fully understand its mechanisms.

    With the rise in interest of various psychedelic drugs for a range of conditions (MDMA for PTSD, and ketamine and psilocybin mushrooms for treatment-resistant depression, to name a few), it seems only fair that we should pay serious attention to other substances in this family that might treat other conditions.

    Introducing ibogaine. Well, not quite introducing. The fairly-obscure African plant, used traditionally in Gabon, was first patented in the United States for use in treating opioid addiction in 1985. Unlike common street drugs such as MDMA (“ecstasy,” “molly”), ibogaine does not have the reputation of being known as a club drug.

    Like Years of Therapy in One Day

    But Ibogaine is still relatively unknown, despite a guest appearance in an early episode of Homeland. When I have advocated for its use in combating our nation’s opioid crisis, most of the responses range from a confused “What?” to an inquisitive “Oh, yeah. I’ve heard of that.” It isn’t a cheap thrill, something folks are clamoring to ingest. People who have found relief with the African root-bark have compared it to receiving years of therapy in the course of one day. The induced vivid hallucinations and memories of childhood and formative experiences seem to facilitate the process of overcoming addictions, even if it isn’t an automatic or guaranteed cure.

    However, that doesn’t mean it’s free of stigma. The federal government classifies it as schedule one – right up there with heroin, the addiction it is most well-known for treating, despite having “no medical use” according to the law. Statistics vary, with some rates as low as 20 percent. Other data shows  61% abstinence, eight months after treatment.

    So, what’s the issue? If this plant boasts a higher success rate than Suboxone (8.6%, once Suboxone use is discontinued), why is it only available outside the U.S.? Why are we not allowing a treatment method that people with opioid use disorder have touted as the thing that saved their lives?

    Why Is Ibogaine Illegal in the U.S.?

    Some of the fault lies with the media. Much like with LSD, clinical studies are slow and evolution of public consciousness is slower. Most of what we see in the news is negative and exaggerated. As with anything, there are risks. Up to 30 deaths have been documented. When people with other health problems related to addiction are treated by those without medical training, death rates can be as high as three percent. In healthy folks, that same rate is around .3%. 

    But when much of what you see in the news and on television is people panicking, convulsing, or dying, it’s tough to form a well-rounded opinion. We are emotional creatures, and even with positive perspectives from people who swear by their experiences, we can’t get the negative images out of our minds for long enough to consider the benefits of ibogaine treatment. 

    Many of the risks involve heart issues. Most psychedelics function as stimulants, raising the heart rate, but ibogaine can be especially cardiotoxic. Ibogaine affects electricity in the heart and could potentially result in dangerous arrhythmias or bradycardia (low heart rate). Because of this and any other possible risks, legitimate clinics pre-screen patients and offer a small test dose to evaluate the effects. Based on the results, they decide if a full dose will be safely tolerated. 

    Like Other Hallucinogenics, Proven Benefits but Not a Panacea

    The substance seems to work due to the uniqueness of the experience. I’ve read multiple accounts of people having vivid visions of the choices they made, and how they’ve arrived at this particular point in their life. This type of experience seems to be the key to its effectiveness in treating severe opioid and alcohol addictions, but experts don’t fully understand its mechanisms.

    And yet, even with its proven benefits, it’s not a panacea. The person with the addiction cannot just visit a clinic, have an ibogaine experience, and expect to return home without changing anything. There is still a rate of relapse, because they haven’t worked on the external triggers. They must still tackle their disease in a proactive way, which may include altering their life and addressing what led to using in the first place.

    Unlike commonly-used routes of getting off opioids – substitution medications such as methadone and Suboxone – ibogaine doesn’t require a patient to remain on another drug, taking it day in and day out to avoid experiencing cravings or going into withdrawal. Ibogaine seems to work by disrupting the receptors associated with addictive behaviors, as was witnessed in one 2015 study on its efficacy in opioid addiction.

    Scientists found that the substance (which, I learned, doesn’t always produce the talked-about hallucinogenic effects that led to its illegal status) acts on receptors such as dopamine and serotonin, which are linked to addiction and the brain’s reward system. Other psychedelics that are currently being studied for their effects on mental illness and addiction – such as MDMA and psilocybin mushrooms – make use of these same receptors. What makes ibogaine unique is that, rather than attaching to receptors on the outside of a cell membrane, it attaches to the inside. This mechanism seems to be unique to ibogaine; it has not been observed in any other naturally occurring molecule.

    Legal Status of Treatment Creates Financial Barrier and Increased Risk

    A major barrier to receiving an ibogaine treatment is the prohibitive cost. A single week of treatment in Mexico costs $5,000, and that’s after the price of a plane ticket. In Canada, the price for a ten-day round is $8,000. As a result, it’s not an option that’s available to most people in need of addiction treatment.

    We must legalize it here. International travel, necessary funds, time off from your job to recover – all these restrictions make it virtually impossible for the average person with treatment-resistant addiction to crack the barriers of that final, desperate chance at a life beyond drugs or alcohol.

    There is a strong, tight-knit movement of psychedelic therapists, but due to the criminalized status of what should be viewed as medicine, those involved with administering these substances remain underground, increasing risks. Even though many of these practitioners are medical doctors, they work without the support of a hospital or facility. While their willingness to practice this medicine outside of the law is a testament to their belief in its efficacy, it also means they are less able to quickly and safely address problems that may come up.

    Who knows what the genuine death toll of ibogaine is in the U.S.? It’s not likely that underground doctors are reporting these deaths to nurses and other hospital staff. If so, they’d be discovered, in turn ruining their careers and possibly derailing the entire growing movement. At least, that’s what instinct tells me. If nothing else, with the substance legalized, fewer deaths and injuries would occur due to more rigorous testing and administering – and consequently fewer accidents would happen as well.

    Ibogaine has shown lasting benefits in treating addiction, as many people attest. One patient was quoted as saying: “It’s not just [that] it gets you off the heroin, it’s like, it hits the reset button — that’s the only way to really explain it. It’s like a new brain.” Shouldn’t we be listening to the voices of people who have actually been there, rather than tossing their words to the wind and sticking with what hasn’t worked?

    View the original article at thefix.com

  • Activists Want Legalization For Psychedelics

    Activists Want Legalization For Psychedelics

    Oakland activists are holding a rally to push for the legalization of psychedelic drugs. 

    As legalized marijuana creeps into the mainstream, advocates for drug policy reform are setting their sights on a new goal—legalizing psychedelics. 

    Organizers in Oakland, California are the latest to push for legalizing psychedelic drugs including mushrooms, according to Marijuana Moment

    A Meetup post advertising efforts to “decriminalize nature” invites people to participate in a rally on March 22 in the city. 

    “With your help we can make this happen, but we need everybody’s support. Join the movement to restore our relationship to nature and advocate for our inalienable right to cognitive liberty and the freedom to explore our own consciousness,” the post reads.

    It continues, “Wouldn’t it be nice to have the freedom to work with these ancient sacred medicines that offer direct knowledge without the fear of persecution? Wouldn’t it be nice to address the set and setting elephant in the room—to reduce the immediate fear of persecution involved while engaging our right to access natural healing and insight—by decriminalizing entheogenic plants and fungi?”

    A representative of the meetup told Marijuana Moment that more details would be shared at the rally. 

    The event in Oakland isn’t entirely unusual. In Denver, an area that helped lead the movement to legalize marijuana, voters will consider a ballot measure to decriminalize psilocybin mushrooms in May. The effort is lead by Decriminalize Denver, and director Kevin Matthews said that just getting the measure on the ballot is significant. 

    “This has never been done before in the history of the U.S., so the fact that we were able to turn out the signatures and make the ballot is a strong statement that there are a lot of people who support this,” Matthews told Marijuana Moment. “We’ve created a platform where we can spread the right information about psilocybin as opposed to the misinformation and, really just downright propaganda from the government, and the war on drugs for the last almost 50 years now.”

    Matthews said that if decriminalization passes in Denver, the group may focus on more widespread change to laws regulating psychedelics. 

    He said, “We are confident that when this passes in May that it’ll open some doors to further conversation. Our big mission here is to work on reintegrating psilocybin back into society.”

    In Iowa, a new Republican lawmaker, Rep. Jeff Shipley, submitted legislation that would allow psilocybin, MDMA and ibogaine to be used in medical treatments by removing a ban on them. 

    “Exploring these issues are paramount to solving the healthcare crisis,” Shipley said in an email to Marijuana Moment. “There’s so much potential for research and clinical applications. I hope we can empower and trust patients to make their own best decisions.”

    View the original article at thefix.com

  • Gwyneth Paltrow Thinks Psychedelic Drugs May Be Next Wellness Trend

    Gwyneth Paltrow Thinks Psychedelic Drugs May Be Next Wellness Trend

    Paltrow believes that ibogaine—a psychoactive substance made from a West African plant—has the potential to help the culture “evolve,”

    No one really knows what’s next in the wellness world — but according to Gwyneth Paltrow, it may be psychedelic drugs.

    In a recent interview with the New York Times, the actress and founder of the wellness brand goop was asked about what may be the next big thing. 

    “I think how psychedelics affect health and mental health and addiction will come more into the mainstream,” she told the Times. “I mean there’s undeniably some link between being in that state and being connected to some other universal cosmic something.”

    Paltrow tells the Times that she has never tried any type of psychoactive drug herself, though she said she believes that ibogaine — a psychoactive substance made from a West African plant —  has the potential to help the culture “evolve,” according to Page Six

    Paltrow told the Times that she and goop have been ahead of the curve with other trends. 

    “When we talk about something that is incendiary, I always see in six months other people starting to write about it, and 18 months later, businesses popping up around it,” she said. “It’s always confirmation to me that we’re on the right track. I mean, when I did my gluten-free cookbook in 2015, the press was super negative and there were personal attacks about what I was feeding my children and what kind of mother I am. Now the gluten-free market is huge.”

    Paltrow began goop about 10 years ago as a newsletter of sorts, and in the time since it has grown into a “modern lifestyle brand,” according to the website. 

    “We believe that the little things count, that good food is the foundation of love and wellness, that the mind/body/spirit is inextricably linked, and we have more control over how we express our health than we currently understand,” goop’s website reads.  

    In the past, according to Page Six, goop has faced some backlash for its “misleading” claims and it even paid $145,000 in civil penalties in September of last year in a case involving a vaginal egg. 

    Paltrow acknowledges the company’s mistakes, but says it never has claimed to be “prescriptive” with its recommendations. 

    “When we were young and not even monetizing the business and just sort of creating content, we didn’t necessarily understand anything about claims. We just thought, ‘Oh, this is a cool alternative modality, let’s write about it,’” she told the Times. “Of course we’ve made some mistakes along the way, but we’ve never been prescriptive. We’ve never said, ‘You should try this,’ or ‘This works.’ We’re just saying, ‘Wow, this is interesting, let’s have a Q and A with this person who practices this.’ And then that somehow gets translated into, ‘Gwyneth says you should do this.’”

    View the original article at thefix.com